Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director · Chairman & CEO | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 566,683 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Sale · Disposed 12,000 · Balance 569,683 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2: Sale prices for the transactions reported range from $147.21 to $148.205. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 2 · 2026-10-01 · Sale · Disposed 3,000 · Balance 566,683 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F3: Sale prices for the transactions reported range from $148.23 to $149.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
F2: Sale prices for the transactions reported range from $147.21 to $148.205. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3: Sale prices for the transactions reported range from $148.23 to $149.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2021 Filed Mar 3, 2021 18:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-009014 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 42,923 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-009014 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 59,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002912 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,670 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 1, 2019, and March 10, 2020. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 43,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010513 · form4.xml · derivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,132 Underlying: Common Stock · 43,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 256,620 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001127602-20-010513 · form4.xml · derivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,620 Underlying: Common Stock · 256,620 shares Expires 2030-03-10 F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 42,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009245 · form4.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,932 Underlying: Common Stock · 42,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 11,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009245 · form4.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,857 Underlying: Common Stock · 11,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 25,922 | $69.36 | $1,797,949.92 |
DisclosureSEC source: 0001127602-20-009245 · form4.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,570 Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 42,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009245 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009245 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 23:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 19,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-002971 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,204 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 1, 2019. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 00:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 128,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-010113 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,220 Underlying: Common Stock · 128,770 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 1/3 will vest on the anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 1/3 will vest on the anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 00:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 45,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-010113 · form4.xml · derivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,450 Underlying: Common Stock · 45,450 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 00:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 231,280 | $0.00 Strike: $66.01 | $0.00 |
DisclosureSEC source: 0001127602-19-010113 · form4.xml · derivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,280 Underlying: Common Stock · 231,280 shares Expires 2029-03-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.